(Q51566279)

English

Randomized, double-blind, placebo-controlled study of the effects of raloxifene and conjugated equine estrogen on plasma homocysteine levels in healthy postmenopausal women.

scientific article published in December 1998

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

7 April 2018

http://europepmc.org/abstract/MED/9848300

Randomized, double-blind, placebo-controlled study of the effects of raloxifene and conjugated equine estrogen on plasma homocysteine levels in healthy postmenopausal women. (English)

1 reference

Europe PubMed Central

PubMed publication ID

7 April 2018

http://europepmc.org/abstract/MED/9848300

author name string

Mijatovic V

1

1 reference

Europe PubMed Central

PubMed publication ID

7 April 2018

http://europepmc.org/abstract/MED/9848300

Netelenbos C

2

1 reference

Europe PubMed Central

PubMed publication ID

7 April 2018

http://europepmc.org/abstract/MED/9848300

van der Mooren MJ

3

1 reference

Europe PubMed Central

PubMed publication ID

7 April 2018

http://europepmc.org/abstract/MED/9848300

de Valk-de Roo GW

4

1 reference

Europe PubMed Central

PubMed publication ID

7 April 2018

http://europepmc.org/abstract/MED/9848300

Jakobs C

5

1 reference

Europe PubMed Central

PubMed publication ID

7 April 2018

http://europepmc.org/abstract/MED/9848300

Kenemans P

6

1 reference

Europe PubMed Central

PubMed publication ID

7 April 2018

http://europepmc.org/abstract/MED/9848300

language of work or name

0 references

publication date

1 December 1998

1 reference

Europe PubMed Central

PubMed publication ID

7 April 2018

http://europepmc.org/abstract/MED/9848300

Fertility and Sterility

1 reference

Europe PubMed Central

PubMed publication ID

7 April 2018

http://europepmc.org/abstract/MED/9848300

70

1 reference

Europe PubMed Central

PubMed publication ID

7 April 2018

http://europepmc.org/abstract/MED/9848300

6

1 reference

Europe PubMed Central

PubMed publication ID

7 April 2018

http://europepmc.org/abstract/MED/9848300

1085-1089

1 reference

Europe PubMed Central

PubMed publication ID

7 April 2018

http://europepmc.org/abstract/MED/9848300

A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2898%2900381-1

7 January 2021

A prospective study of plasma homocyst(e)ine and risk of myocardial infarction in US physicians

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2898%2900381-1

7 January 2021

Plasma homocysteine levels and mortality in patients with coronary artery disease

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2898%2900381-1

7 January 2021

Plasma homocysteine and menopausal status.

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2898%2900381-1

7 January 2021

Postmenopausal Estrogen and Progestin Use and the Risk of Cardiovascular Disease

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2898%2900381-1

7 January 2021

Hormone replacement therapy and cardioprotection: basic concepts and clinical considerations

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2898%2900381-1

7 January 2021

Hormone replacement therapy may reduce high serum homocysteine in postmenopausal women.

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2898%2900381-1

7 January 2021

Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Collaborative Group on Hormonal Factors in Breast Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2898%2900381-1

7 January 2021

Identification of an estrogen response element activated by metabolites of 17beta-estradiol and raloxifene

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2898%2900381-1

7 January 2021

Raloxifene (LY139481 HCI) prevents bone loss and reduces serum cholesterol without causing uterine hypertrophy in ovariectomized rats

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2898%2900381-1

7 January 2021

A controlled trial of raloxifene (LY139481) HCl: impact on bone turnover and serum lipid profile in healthy postmenopausal women

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2898%2900381-1

7 January 2021

Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2898%2900381-1

7 January 2021

Fatal myocardial infarction in the Scottish adjuvant tamoxifen trial. The Scottish Breast Cancer Committee

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2898%2900381-1

7 January 2021

Rapid high-performance liquid chromatographic assay for total homocysteine levels in human serum

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2898%2900381-1

7 January 2021

A randomized controlled study of the effects of 17beta-estradiol-dydrogesterone on plasma homocysteine in postmenopausal women.

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2898%2900381-1

7 January 2021

Postmenopausal oral 17beta-estradiol continuously combined with dydrogesterone reduces fasting serum homocysteine levels.

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2898%2900381-1

7 January 2021

Plasma levels of the atherogenic amino acid homocysteine in post-menopausal women with breast cancer treated with tamoxifen

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2898%2900381-1

7 January 2021

Homocysteinemia: association of a metabolic disorder with vascular disease and thrombosis

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2898%2900381-1

7 January 2021

Homocysteine and hemostasis: pathogenic mechanisms predisposing to thrombosis

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2898%2900381-1

7 January 2021

Hyperhomocyst(e)inemia is associated with impaired endothelium-dependent vasodilation in humans.

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2898%2900381-1

7 January 2021

Cortisol and estradiol: nongenetic factors for hyperhomocyst(e)inemia

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2898%2900381-1

7 January 2021

Differences between premenopausal women and young men in the transamination pathway of methionine catabolism, and the protection against vascular disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2898%2900381-1

7 January 2021

Identifiers

10.1016/S0015-0282(98)00381-1

1 reference

Europe PubMed Central

PubMed publication ID

7 April 2018

http://europepmc.org/abstract/MED/9848300

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

7 April 2018

http://europepmc.org/abstract/MED/9848300

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q51566279&oldid=1373376760"